x

Posted 12 May, 2023

Biofrontera Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:BFRI in a 8-K filed on 12 May, 2023.


  On May 8, 2023, Erica Monaco, Chief Executive Officer of the Company notified the Company's Board of Directors that she intends to resign from the Company to pursue other opportunities.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Biofrontera Inc.
Health Care/Life Sciences • Pharmaceuticals
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
Market Cap
$2.27M
View Company Details
Biofrontera Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 


On May 8, 2023, Erica Monaco, Chief Executive Officer of the Company notified the Company's Board of Directors that she intends to resign from the Company to pursue other opportunities. The Company and Ms. Monaco have agreed to discuss an appropriate transition period, including the effective date of her resignation.